Australian Clinical Labs
Australian Clinical Labs is a leading provider of pathology services in Australia, offering a comprehensive range of diagnostic testing services. The company operates over 50 NATA-accredited laboratories and more than 1,200 collection centers, serving a diverse clientele. Its commitment to quality and innovation positions it as a key player in the healthcare sector.
Short position
Australian Clinical Labs (ASX:ACL) has 4.39% of its shares on issue reported as short positions as of 5 Oct 2026, or about 8,197,284 shares. Over the past 30 days that figure has fallen 0.43 percentage points, and over 90 days it has fallen 3.17 percentage points. Its highest recorded short interest was 11.19% in July 2024. ACL is classified in the Health Care Equipment & Services industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Australian Clinical Labs (ACL) financials
Results, ratios and statements
Latest result
Year to 30 Jun 2026 (FY26) vs FY25, figures in AUD, the reporting currency
- Revenue
- $735.8MM (source: ASX (Markit))vs $736.1M (FY25)
- ASX (Markit), as at 29 Sep 2026
- NPAT
- $23.7MM (source: ASX (Markit))vs $32.4M (FY25)
- ASX (Markit), as at 29 Sep 2026
- EPS (diluted)
- $0.12T (source: Derived: trailing 12 months at year end)vs $0.17 (FY25)
- Derived: trailing 12 months at year end, as at 29 Sep 2026
- Rev YoY
- −0.1%FY
- EPS YoY
- −27.7%TTM
- ASX (Markit)
- Derived: trailing 12 months at year end
Key ratios
Year to 30 Jun 2026 (FY); no balance sheet aligned with this period; prices to 9 Oct 2026
- Gross margin
- n/a
- Operating margin
- n/a
- Net margin
- 3.2%
- FCF margin
- n/a
- ROE
- n/a
- ROA
- n/a
- FCF conversion
- n/a
- Net debt (excl. leases)
- n/a
- Net debt / EBITDA
- n/a
- Current ratio
- n/a
- Interest cover
- n/a
- Cash dividends paid / net profit
- n/a
- Market cap
- n/a (no share count we can vouch for)
- P/E
- 23.8×
- P/B
- n/a (no share count we can vouch for)
Ratios use the reporting currency (AUD); market cap is in AUD. Source: ASX (Markit), as at 29 Sep 2026.
Financial statements
Figures in AUD, the reporting currency; Yahoo Finance unless marked
| Line item | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Revenue | $735.8MM (source: ASX (Markit)) | $736.1M | $689.7M | $692.1M |
| Gross profit | n/a | $607.9M | $570.4M | $566.0M |
| Operating income | n/a | $62.9M | $55.9M | $52.0M |
| EBITDA | n/a | $188.0M | $169.7M | $174.6M |
| EBIT | n/a | $52.0M | $41.2M | $51.9M |
| Interest expense | n/a | $3.8M | $4.9M | $3.5M |
| Pretax income | n/a | $48.2M | $36.4M | $48.3M |
| Tax | n/a | $15.4M | $12.1M | $12.3M |
| NPAT | $23.7MM (source: ASX (Markit)) | $32.4M | $23.9M | $35.9M |
| Net interest income | n/a | −$18.0M | −$16.5M | −$13.7M |
| EPS basic | $0.12T (source: Derived: trailing 12 months at year end) | $0.17 | $0.12 | $0.18 |
| EPS diluted | $0.12T (source: Derived: trailing 12 months at year end) | $0.17 | $0.12 | $0.18 |
| Shares | n/a | 195.8M | 201.8M | 201.8M |
- ASX (Markit)
- Derived: trailing 12 months at year end
Financial reports
The company's own filings, newest first
- 2026 Annual ReportAnnual Report22 Sep 2026via asx_announcements
- FY26 financial results investor presentationFinancial Report17 Aug 2026via asx_announcements
- Appendix 4E and FY26 financial reportsAnnual Results17 Aug 2026via asx_announcements
- Appendix 4D and 1H26 financial reportsHalf Year Results16 Feb 2026via asx_announcements
- ACL 1H26 financial results investor presentationFinancial Report16 Feb 2026via asx_announcements
- 2025 Annual ReportAnnual Report19 Sep 2025via asx_announcements
- Appendix 4E and Financial Report 30 June 2025Annual Results26 Aug 2025via asx_announcements
- Investor webinar - FY25 financial resultsFinancial Report19 Aug 2025via asx_announcements
- FY25 financial results and AGMFinancial Report5 Aug 2025via asx_announcements
- Appendix 4D and 1H25 financial statementsHalf Year Results26 Feb 2025via asx_announcements
Showing 10 of 26 reports